UDG Healthcare Public Limited Co. Notice of Preliminary Results (1671G)
November 02 2018 - 04:59AM
UK Regulatory
TIDMUDG
RNS Number : 1671G
UDG Healthcare Public Limited Co.
02 November 2018
2 November 2018
UDG Healthcare plc
Notice of Preliminary Results
UDG Healthcare plc ("the Group"), a leading international
healthcare services provider, will issue its full year results for
the year ending 30 September 2018 at 07:00am (GMT) on Tuesday 27
November 2018.
Brendan McAtamney, Chief Executive Officer, and Nigel Clerkin,
Chief Financial Officer, will be hosting a presentation for
analysts and investors at the London Stock Exchange at 08:30am
(GMT) to discuss the company's full year results and provide an
update on each of the Group's divisions. They will be joined for a
Q&A session by other members of the divisional management
team.
Analysts and investors wishing to attend are asked to contact
Powerscourt on the details below, as all attendees need to be
pre-registered. The presentation will also be available via live
audio webcast and conference call, the details of which are
below.
Audio webcast:
https://edge.media-server.com/m6/p/njnoc85w
Conference call dial-in details:
UK +44 (0)330 336 9105
Ireland +353 (0)1 246 5638
--------------------
United States of America +1 929-477-0448
--------------------
Participant Code 7295026
--------------------
For further information, please contact:
UDG Healthcare plc
Keith Byrne
Head of Investor Relations, Strategy & Corporate
Communications
Tel: +353-1-468-9000
Powerscourt
Lisa Kavanagh / Jana Tsiligiannis / Sam Austrums
Tel: +44-207-250-1446
udghealthcare@powerscourt-group.com
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a leading international partner
of choice delivering advisory, communication, commercial, clinical
and packaging services to the healthcare industry, employing over
8,500 people with operations in 26 countries and delivering
services in over 50 countries.
UDG Healthcare plc operates across two divisions: Ashfield and
Sharp.
Ashfield is a global leader in advisory, communication,
commercial and clinical services for the pharmaceutical and
healthcare industries.
It focuses on supporting healthcare professionals and patients
at all stages of the product life cycle. The division provides
field and contact centre sales teams, healthcare communications,
patient support, audit, advisory, medical information and event
management services to over 300 healthcare companies.
Sharp is a global leader in contract commercial packaging and
clinical trial packaging services for the pharmaceutical and
healthcare industries, operating from state-of-the-art facilities
in the US and Europe.
The company is listed on the London Stock Exchange and is a
constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORKMMGMRZKGRZG
(END) Dow Jones Newswires
November 02, 2018 04:59 ET (08:59 GMT)
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Udg Healthcare Public (LSE:UDG)
Historical Stock Chart
From Mar 2023 to Mar 2024